<PAGE>
================================================================================
U. S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-QSB
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2000
------------------
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Commission File Number 0-27264
GenStar Therapeutics Corporation
(formerly Urogen Corp.)
(Exact name of registrant as specified in its charter)
DELAWARE
--------
(State or other jurisdiction of
incorporation or organization)
33-0687976
----------
(I.R.S. Employer
Identification no.)
10865 Altman Row, San Diego, CA, 92121
(Address of principal executive offices) (Zip code)
Registrant's Telephone Number, including area code: (858) 450-5949
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No_____
-----
The number of shares of the Common Stock of the registrant outstanding as of
October 31, 2000, was 22,639,612.
<PAGE>
GenStar Therapeutics Corporation
(Formerly UroGen Corp.)
(A Development Stage Enterprise)
INDEX TO FORM 10-QSB
PART I. FINANCIAL INFORMATION
------------------------------
<TABLE>
<CAPTION>
Page No.
--------
<S> <C>
Item 1. Financial Statements
Condensed Consolidated Balance Sheets
September 30, 2000 (Unaudited) and December 31, 1999...... 2
Condensed Consolidated Statements of Operations (Unaudited)
Three and Nine months Ended September 30, 2000 and
1999 and the period from July 1, 1991 (inception)
to September 30, 2000...................................... 3
Condensed Consolidated Statements of Cash Flows (Unaudited)
Nine months Ended September 30, 2000 and
1999 and the period from July 1, 1991 (inception)
to September 30, 2000...................................... 4
Notes to Unaudited Condensed Consolidated
Financial Statements....................................... 5
Item 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations.............. 6
PART II. OTHER INFORMATION
---------------------------
Item 1. Legal Proceedings............................................ 10
Item 2. Changes in Securities........................................ 10
Item 3. Defaults Upon Senior Securities.............................. 10
Item 4. Submission of Matters to a Vote of Security Holders.......... 10
Item 5. Other Information............................................ 10
Market For Registrant's Common Equity
Item 6. Exhibits and Reports on Form 8-K............................. 10
Signatures................................................... 11
</TABLE>
1
<PAGE>
GENSTAR THERAPEUTICS CORPORATION
(Formerly UroGen Corp.)
(A DEVELOPMENT STAGE ENTERPRISE)
CONDENSED CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
September 30, December 31,
2000 1999
---- ----
(Unaudited) (Note)
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 9,019,425 $ 921,994
Short-term investments 15,140,534 -
Accounts receivable 13,421 114,208
Other current assets 70,392 9,461
------------ ------------
Total current assets 24,243,772 1,045,663
Property and equipment, net 1,798,824 569,121
Investments underlying deferred compensation 157,603 134,308
Other assets 77,990 77,821
------------ ------------
$ 26,278,189 $ 1,826,913
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable $ 616,800 $ 399,485
Accrued employee benefits 171,167 73,915
Other accrued liabilities 103,813 81,856
Current portion of notes payable 265,569 -
Current portion of capital lease obligation 77,058 42,696
------------ ------------
Total current liabilities 1,234,407 597,952
Notes payable, net of current portion 591,641 -
Capital lease obligation, net of current portion 76,038 51,314
Deferred compensation 364,559 206,962
Advance from related party 6,018,672 1,876,003
Commitments
Stockholders' equity (deficit):
Preferred Stock - $0.01 par value, 5,000,000 shares authorized:
Series A Preferred Stock, 5,830 and 5,830 shares
issued and outstanding 58 58
Series B Preferred Stock, 2,998 and 2,998 shares
issued and outstanding 30 30
Common Stock - $0.001 par value, 40,000,000
shares authorized; 22,597,880 and 12,104,101 shares
issued and outstanding 22,598 12,104
Unrealized loss on investments (9,418) -
Additional paid-in capital 37,160,754 11,606,880
Deficit accumulated during development stage (19,181,150) (12,524,390)
------------ ------------
Total stockholders' equity (deficit) 17,992,872 (905,318)
------------ ------------
$ 26,278,189 $ 1,826,913
============ ============
</TABLE>
Note: The balance sheet at December 31, 1999 is derived from the audited
balance sheet at that date, but does not include all of the footnote disclosures
required by generally accepted accounting principles.
See accompanying notes.
2
<PAGE>
GENSTAR THERAPEUTICS CORPORATION
(Formerly UroGen Corp.)
(A Development Stage Enterprise)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended Nine months Ended July 1, 1991
------------------ -----------------
(inception) to
September 30, September 30, September 30, September 30, September 30,
2000 1999 2000 1999 2000
---- ---- ---- ---- ----
<S> <C> <C> <C> <C> <C>
Revenue $ 40,263 $ 16,389 $ 113,396 $ 67,201 $ 1,072,643
----------- ----------- ----------- ----------- ------------
Costs and expenses:
Cost of sales - - - - 821,878
Research and development 1,808,407 714,908 4,232,738 1,861,892 12,378,327
Write-off of acquired in-process technology 21,718 - 1,654,924 - 7,110,429
General and administrative 653,269 185,751 1,656,647 591,777 3,820,711
----------- ----------- ----------- ----------- ------------
Total costs and expenses 2,483,394 900,659 7,544,309 2,453,669 24,131,345
----------- ----------- ----------- ----------- ------------
Loss from operations (2,443,131) (884,270) (7,430,913) (2,386,468) (23,058,702)
Other income (expense) 53 - (17,140) 905 (24,813)
Interest expense (19,115) - (71,076) (348,890) (737,599)
Interest income 364,550 7,454 862,369 15,292 914,171
----------- ----------- ----------- ----------- ------------
Net loss $(2,097,643) $ (876,816) $(6,656,760) $(2,719,161) $(22,906,943)
=========== =========== =========== =========== ============
Basic and diluted loss per share $ (0.09) $ (0.07) $ (0.33) $ ( 0.27)
=========== =========== =========== ===========
Number of shares used in the computation of
basic and diluted loss per share 22,475,760 12,097,999 20,456,711 10,237,493
=========== =========== =========== ===========
</TABLE>
See accompanying notes.
3
<PAGE>
GENSTAR THERAPEUTICS CORPORATION
(Formerly UroGen Corp.)
(A Development Stage Enterprise)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
<TABLE>
<CAPTION>
July 1, 1999
For the nine months ended (inception) to
September 30, September 30,
2000 1999 2000
---- ---- ----
<S> <C> <C> <C>
Net loss $ (6,656,760) $(2,719,161) $(22,906,943)
Adjustments to reconcile net loss to net cash used
in operating activities:
Write-off of in-process technology acquired with stock 1,519,500 - 6,975,005
Expenses paid via advances from related party - - 695,557
Depreciation and amortization 240,663 89,491 891,515
Accrued interest paid through issuance of common stock - 42,563 40,245
Non-cash expense related to stock awards and stock
options issued 307,804 2,900 434,854
Loss (gain) on disposal of fixed assets 363 - (81,444)
Amortization of debt discount - 305,428 574,296
Change in assets and liabilities:
Accounts receivable 100,787 - (13,421)
Other current assets (60,931) (2,648) (70,392)
Other assets (23,464) (188,500) (235,593)
Accounts payable 217,315 (163,508) 616,800
Amounts due to stockholder - (315,000) -
Other current liabilities 58,428 (88,557) 256,895
Deferred compensation 157,597 121,657 364,559
------------ ----------- ------------
Net cash used in operating activities (4,138,698) (2,915,335) (12,458,067)
Cash flows from investing activities:
Purchase of short-term investments (15,149,952) - (15,149,952)
Purchase of property and equipment (1,163,751) (65,048) (1,912,669)
------------ ----------- ------------
Net cash used in investing activities (16,313,703) (65,048) (17,062,621)
Cash flows from financing activities:
Advances from related party 4,142,669 3,401,670 8,321,115
Repayment of note receivable from stockholder - 20,000 20,000
Proceeds from notes payable 750,000 400,000 2,180,000
Repayment of capital leases and notes payable (140,688) - (151,329)
Proceeds from issuance of common stock upon exercise of
options and warrants 371,873 1,729 444,102
Proceeds from sale of common stock, net of issuance costs 23,425,978 - 23,342,760
Net advances from Medstone - - 3,883,465
Capital contribution by Medstone - - 500,000
------------ ----------- ------------
Net cash provided by financing activities 28,549,832 3,823,399 38,540,113
------------ ----------- ------------
Net increase in cash and cash equivalents 8,097,431 843,016 9,019,425
Cash and cash equivalents, beginning of period 921,994 314,983 -
------------ ----------- ------------
Cash and cash equivalents, end of period $ 9,019,425 $ 1,157,999 $ 9,019,425
============ =========== ============
</TABLE>
See accompanying notes.
4
<PAGE>
GENSTAR THERAPEUTICS CORPORATION
(Formerly UroGen Corp.)
(A Development Stage Enterprise)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2000
1. The unaudited financial information furnished herein, in the opinion of
management, reflects all adjustments, consisting only of normal recurring
adjustments, which are necessary to state fairly the consolidated financial
position, results of operations, and cash flows of GenStar Therapeutics
Corporation as of and for the periods indicated. GenStar presumes that
users of the interim financial information have read or have access to the
Company's audited consolidated financial statements and Management's
Discussion and Analysis of Financial Condition and Results of Operations
for the year ended December 31, 1999 and that the adequacy of additional
disclosure needed for a fair presentation, except in regard to material
contingencies or recent significant events, may be determined in that
context. Accordingly, footnote and other disclosures which would
substantially duplicate the disclosures contained in Form 10-KSB for the
year ended December 31, 1999 filed on March 30, 2000 by the Company have
been omitted. The interim financial information herein is not necessarily
representative of a full year's operations.
2. Cash and cash equivalents consist primarily of highly liquid investments
with original maturities of 90 days or less when purchased. Short-term
investments consist of debt and equity securities with maturities in excess
of 90 days when purchased. In accordance with the Financial Accounting
Standards Board's Statement of Financial Accounting Standards ("SFAS") No.
115, Accounting for Certain Investments in Debt and Equity Securities,
management determines the appropriate classification of short-term
investment securities at the time of purchase and reevaluates such
designation as of each balance sheet date. Securities classified as
available-for-sale are carried at fair value, with gains and losses, if
any, reported as a separate component of stockholders' equity and included
in comprehensive loss.
3. In accordance with SFAS No. 128, Earnings per Share, net loss per share is
based on the average number of shares of common stock outstanding during
the nine-month periods ended September 30, 2000 and 1999. Equivalent shares
arising from convertible preferred stock, convertible debt, warrants for
Common Stock and outstanding stock options have not been included in the
computation of net loss per share as their effect would be antidilutive.
4. In January and February 2000, the Company issued 8,362,801 shares of Common
Stock and warrants to purchase an additional 1,773,899 shares of Common
Stock for total gross proceeds of $25,309,000. The warrants are exercisable
for five years and have an exercise price of $0.75 per share.
5
<PAGE>
GENSTAR THERAPEUTICS CORPORATION
(Formerly UroGen Corp.)
(A Development Stage Enterprise)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(continued)
September 30, 2000
5. SFAS No. 130, Reporting Comprehensive Income ("SFAS 130"), requires
reporting and displaying comprehensive income (loss) and its components
which, for the Company, includes net loss and unrealized gains and losses
on investments. In accordance with SFAS 130, the accumulated balance of
other comprehensive income is disclosed as a separate component of
stockholders' equity (deficit). For the three and nine months ended
September 30, 2000 and 1999, respectively, the comprehensive loss consisted
of:
<TABLE>
<CAPTION>
Three months ended Nine months ended
September 30, September 30,
----------------------------------------------------------
2000 1999 2000 1999
---- ---- ---- ----
<S> <C> <C> <C> <C>
Net loss $(2,097,643) $(876,816) $(6,656,760) $(2,719,161)
Other comprehensive loss:
Unrealized loss on investments (9,418) - (9,418) -
----------- --------- ----------- -----------
Comprehensive loss $(2,107,061) $(876,816) $(6,666,178) $(2,719,161)
=========== ========= =========== ===========
</TABLE>
6. On May 15, 2000 the Company acquired all of the outstanding shares of
Allegro Cell Systems, Inc. (Allegro) in exchange for 288,000 shares of
GenStar common stock, and an obligation to issue an additional 12,000
shares of common stock. Allegro has a license to certain technologies for
the treatment and prevention of AIDS and for lentiviral gene therapy.
Allegro has no products, revenues, employees, facilities or other assets.
The shares issued to acquire the technologies were valued at $1,519,500
based on the fair market value of our common stock on the date of the
agreement and was charged to acquired in-process technology due to the
early stage of development of the technology and the lack of alternative
future uses for it.
7. During the nine months ended 1999 and 2000, respectively, the Company
acquired equipment valued at $118,000 and $96,000 under capital lease
agreements. During the nine months ended 2000, the Company acquired
leasehold improvements valued at $200,000 under a note payable.
During the none months ended 1999, convertible notes payable and accrued
interest in the amount of $1,512,000 converted into 2,460,811 shares of
Common Stock. Additionally, during same period, amounts due Baxter under
the credit agreement of $704,000 were converted into 704 shares of Series B
Preferred Stock.
Cash paid for income taxes during the nine months ended 1999 and 2000 was
$2,500 and $1,700, respectively. Cash paid for interest during the nine
months ended 1999 and 2000 was none and $46,000.
8. Effective January 1, 2001, the Company will adopt SFAS No. 133, Accounting
for Derivative Instruments and Hedging Activities. The adoption of SFAS No.
133 is not anticipated to have an impact on the Company's results of
operations or financial condition as the Company holds no derivative
instruments and does not currently invest in derivative instruments or
engage in hedging activities.
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operation
OVERVIEW
GenStar Therapeutics Corporation changed its name from UroGen Corp. in March
2000. GenStar commenced operations as a stand-alone entity in January 1996 and
has been in the development stage since inception. Our original mission was to
develop products to treat diseases in urology, with a particular interest in
prostate cancer. We had licensed technology that uses the IL-3 gene to treat
several types of cancer. On July 8, 1998, we entered into an agreement with
Baxter Healthcare Corporation in which we acquired the exclusive rights to gene
delivery technologies and laboratory equipment. The gene delivery technology
will be used to enhance our
6
<PAGE>
existing technology and to develop products to deliver other genes. Prior to our
license of the technology, Baxter had been developing this technology for the
treatment of hemophilia and cancer and has continued to fund the development of
our MAXIMUM-AD product for hemophilia.
In exchange for the exclusive license to the gene delivery technology and
equipment, we issued 1,841,219 shares of common stock and 5,830 shares of Series
A Preferred Stock to Baxter. The assets acquired from Baxter were valued based
on the fair market value of our common stock on the date of the agreement. We
obtained an appraisal of the value of the equipment acquired. Based upon the
very early stage of development of the technology and the lack of alternative
future uses for it, the value of the technology was charged to acquired in-
process technology.
In May 2000, we acquired all of the outstanding shares of Allegro Cell Systems,
Inc. (Allegro) in exchange for 288,000 shares of GenStar Common Stock, and an
obligation to issue an additional 12,000 shares of common stock. Allegro has a
license to certain technologies for the treatment and prevention of AIDS and for
lentiviral gene therapy. Allegro has no products, revenues, employees,
facilities or other assets. Based upon the very early stage of development of
the technology and the lack of alternative future uses for it, the value of the
technology was charged to acquired in-process technology.
The technology for the treatment of AIDS is based upon vaccination with a
genetically modified HIV virus. The modified virus is incapable of replication
and suitable for administration to humans. The modified virus is still capable
of infecting cells and expressing HIV genes resulting in the generation of
immune responses that eradicate HIV infected cells in laboratory studies. The
lentiviral gene therapy delivery technology was designed for therapeutic
applications.
Genstar's current activities consist of the development of the MAXIMUM-AD gene
transfer system for our hemophilia A product, our DUAL-AD vector product for
prostate cancer, and the LENTI-HIV vector system for the treatment of HIV/AIDS.
We anticipate defining additional uses for our vector technologies and
potentially acquiring other technologies. We expect to incur increasing research
and development expenditures as we focus our efforts on further development of
these products. We expect no product revenues in the near future and to incur
significant losses for at least the next five years.
RESULTS OF OPERATIONS
Revenues
GenStar has generated revenues to date of $1,073,000 from contract research
agreements and grants. Total revenues for the nine months ended September 30,
1999 and 2000 were $67,000 and $113,000, respectively, and for the three months
ended September 30, 1999 and 2000 were $16,000 and $40,000, respectively. All
revenue during 1999 and 2000 was from grants. We anticipate seeking additional
research agreements and grants to help fund research and development efforts;
however, we do not expect that contract research will result in significant
revenues in the future. We do not anticipate revenues from products for at least
five years.
Research and development and acquired in-process technology
Research and development and acquired in-process technology expenses increased
$4,026,000 to $5,888,000 during the nine months ended September 30, 2000
compared to $1,862,000 for the nine months ended September 30, 1999. During the
three months ended September 30, 2000 research and development and acquired in-
process technology increased $1,115,000 to $1,830,000 compared to
7
<PAGE>
$715,000 for the three months ended September 30, 1999. Research and development
and acquired in-process technology expenses increased in the first nine months
of 2000 compared to the same period of 1999 due principally to the acquisition
of Allegro, which resulted in a charge to write-off acquired in-process
technology of $1,633,000 during the second quarter and an additional $22,000
during the third quarter of 2000. There were no similar charges in the same
period of 1999. Research and development costs for both the first nine months
and the third quarter of 2000 increased due to an increase in research and
development activity and the commencement of operations of our manufacturing
facility in the first quarter of 2000. We anticipate increasing research and
development expenditures in the future as we conduct preclinical and clinical
testing necessary to bring our products to market and to establish additional
manufacturing capabilities.
General and administrative expense
General and administrative expense increased $1,065,000 during the nine months
ended September 30, 2000 to $1,657,000 compared to $592,000 for the nine months
ended September 30, 1999. During the three months ended September 30, 2000
general and administrative expense increased $467,000 to $653,000 compared to
$186,000 for the three months ended September 30, 1999. General and
administrative expenses include the costs of our administrative personnel and
consultants, office lease expenses and other overhead costs, including legal and
accounting costs. General and administrative expenses have increased related to
the increased level of operations, and we expect general and administrative
expenses to continue to increase to support our increasing research and
development activities.
Interest income and expense
Interest income increased $847,000 during the nine months ended September 30,
2000 to $862,000 compared to $15,000 for the nine months ended September 30,
1999. During the three months ended September 30, 2000 interest income increased
$358,000 to $365,000 compared to $7,000 for the three months ended September 30,
1999. Interest income is a result of the investment of excess cash in money
market accounts, corporate and international bonds and certificates of deposit.
Interest expense decreased $278,000 for the nine months ended September 30, 2000
to $71,000 compared to $349,000 for the nine months ended September 30, 1999.
During the three months ended September 30, 2000 interest expense increased
$19,000 to $19,000 compared to none for the three months ended September 30,
1999. Interest expense in 1999 related to convertible notes payable which were
converted to common stock in June 1999. Interest expense in 2000 relates to
equipment financing and the deferred compensation liability.
LIQUIDITY AND CAPITAL RESOURCES
Net cash used by operating activities during the nine months ended September 30,
1999 and 2000 was $2,915,000 and $4,139,000, respectively. Net cash used by
operating activities consists primarily of GenStar's net loss decreased by non-
cash expenses. Net cash used by investing activities during the nine months
ended September 30, 1999 and 2000 was $65,000 and $16,314,000, respectively. In
1999, net cash used by investing activities consists of the purchase of
furniture and equipment; in 2000, it consists of both the purchase of furniture
and equipment and short-term investments. Net cash provided by financing
activities during the nine months ended September 30, 1999 of $3,823,000
consists primarily of $3,402,000 paid by Baxter under the credit agreement for
development of the hemophilia product and $400,000 of proceeds from convertible
notes payable. Net cash provided by financing activities of $28,550,000 for the
nine months ended September 30, 2000 consists primarily of net proceeds from the
sale of common stock and warrants for common stock of $23,426,000, proceeds from
notes payable of $750,000 and $4,143,000 paid by Baxter under the aforementioned
credit agreement.
8
<PAGE>
GenStar's future capital requirements will depend on many factors, including
scientific progress in our research and development programs, our ability to
establish collaborative arrangements with others for drug development, progress
with preclinical and clinical trials, the time and costs involved in obtaining
regulatory approvals and effective commercialization activities. Medstone
International, Inc. provided GenStar with a $500,000 capital contribution of
cash on February 9, 1996. In July 1998, we completed an offering of 8%
Convertible Subordinated Notes due June 30, 1999, which raised $1,030,000, which
was converted to common stock on June 22, 1999. In April 1999, we completed
another offering of Convertible Subordinated Notes due March 30, 2000, which
raised $400,000, which was converted to common stock on June 22, 1999. During
the quarter ended March 31, 2000, we completed the private placement of
8,362,801 shares of common stock and warrants to purchase an additional
1,773,899 shares of common stock. Net proceeds from these financings was
$23,426,000. GenStar has incurred net losses of $22,907,000 since its inception
and has never been profitable during its existence. We expect to incur
significant additional operating losses over the next several years as our
research and development efforts expand. Our ability to achieve profitability
depends upon our ability, alone or with others, to successfully complete
development of products, obtain required regulatory approvals and manufacture
and market products. We cannot assure that we will be successful or that we
will attain significant revenues or profitability. Our operations to date have
consumed substantial amounts of cash. The negative cash flow from operations is
expected to continue and to accelerate for at least the next five years. The
development of our products will require a commitment of substantial funds to
conduct the costly and time-consuming research, preclinical and clinical testing
necessary to bring our products to market and to establish manufacturing and
marketing capabilities.
Under the terms of our Developmental Collaboration Agreement and Credit
Agreements with Baxter, Baxter will provide funding for development of the
hemophilia product until we commence a Phase I Clinical Trial for the hemophilia
product, at which time a milestone payment of $2,000,000 is due from Baxter. The
funding provided by Baxter is in the form of a note payable, which can be
converted to Series B Preferred Stock at our option on December 31 of each year
of the agreement. The $2,000,000 milestone payment is in the form of a purchase
of Series C Preferred Stock.
We anticipate our existing capital resources, including funds received from
Baxter under the Developmental Collaboration Agreement, will enable us to
maintain our current and planned operations until the middle of the year 2002.
We will need to raise substantial additional capital to fund future operations.
We intend to seek additional funding either through collaborative arrangements
or through public or private equity or debt financings. Additional financing may
not be available on acceptable terms or at all. If adequate funds are not
available, we may be required to delay or reduce the scope of our operations or
to obtain funds through arrangements with collaborative partners or others that
may require us to relinquish rights we may otherwise have.
9
<PAGE>
PART II. OTHER INFORMATION
---------------------------
Item 1. LEGAL PROCEEDINGS
None.
Item 2. CHANGES IN SECURITIES
None.
Item 3. DEFAULTS UPON SENIOR SECURITIES
None.
Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
Item 5. OTHER INFORMATION
Market for Registrant's Common Equity
None of the shares of capital stock of the Company issued in the
Distribution or otherwise, or acquired through the exercise of stock
options could be sold prior to December 31, 1997 except for the following
transfers: (i) transfers by gift, will, bequest or the applicable laws of
descent and distribution; (ii) non-sale distributions by partnerships,
corporations or trusts to their partners, shareholders or beneficiaries;
(iii) transfers to the Company; and (iv) transfers pursuant to qualified
domestic relations order as defined by the Code or the rules thereunder.
In the case of any such permitted transfers, the shares in the hands of
the transferees will continue to be subject to the same transfer
restriction. No market for the Company's shares of capital stock existed
prior to January 1, 1998. The Company trades under the symbol GNT on the
American Stock Exchange.
Item 6. EXHIBITS AND REPORTS ON FORM 8-K
Exhibit 27 Financial Data Schedule
10
<PAGE>
SIGNATURES
In accordance with the requirements of the Exchange Act, the Registrant has
caused this Report to be signed on its behalf by the undersigned, hereunto duly
authorized.
GENSTAR THERAPEUTICS CORPORATION
--------------------------------
A Delaware Corporation
Date: November 2, 2000 /s/ Carin D. Sandvik
-----------------------
Carin D. Sandvik
Controller, Chief Accounting Officer &
Secretary
(Principal financial and accounting officer)
11
